Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other financing activities (2018 - 2024)

Historic Other financing activities for Autolus Therapeutics (AUTL) over the last 7 years, with Q2 2024 value amounting to $1.8 million.

  • Autolus Therapeutics' Other financing activities fell 9981.83% to $1.8 million in Q2 2024 from the same period last year, while for Mar 2025 it was $1.8 million, marking a year-over-year decrease of 9514.05%. This contributed to the annual value of $29.4 million for FY2024, which is 312637.36% up from last year.
  • Autolus Therapeutics' Other financing activities amounted to $1.8 million in Q2 2024, which was down 9981.83% from $27.5 million recorded in Q1 2024.
  • Over the past 5 years, Autolus Therapeutics' Other financing activities peaked at $1.0 billion during Q3 2023, and registered a low of -$7.6 million during Q1 2021.
  • For the 5-year period, Autolus Therapeutics' Other financing activities averaged around $505.9 million, with its median value being $590.4 million (2020).
  • Its Other financing activities has fluctuated over the past 5 years, first tumbled by 10130.4% in 2021, then skyrocketed by 10100420000.0% in 2023.
  • Over the past 5 years, Autolus Therapeutics' Other financing activities (Quarter) stood at $595.0 million in 2020, then plummeted by 98.08% to $11.5 million in 2021, then fell by 9.67% to $10.3 million in 2022, then skyrocketed by 9717.08% to $1.0 billion in 2023, then tumbled by 99.82% to $1.8 million in 2024.
  • Its Other financing activities was $1.8 million in Q2 2024, compared to $27.5 million in Q1 2024 and $1.0 billion in Q3 2023.